跳至主要内容
临床试验/NCT01994356
NCT01994356已完成不适用

Pilot Study of Physician Self-disclosure of Personal Intrauterine Contraceptive Use Versus Usual Counseling

University of Michigan1 个研究点 分布在 1 个国家目标入组 132 人开始时间: 2011年1月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
132
试验地点
1
主要终点
Intrauterine contraceptive use

研究概览

简要总结

As many as one-third of female healthcare providers use intrauterine contraception (IUC), but only about 8 percent of US women overall do. This begs the question: Might physician self-disclosure of personal IUC use increase IUC use among patients? However, the positive or negative impact of physician self disclosure on IUC uptake or patient satisfaction is generally unknown. The purpose of this study was to evaluate if physician self-disclosure of personal IUC use increases patient use of IUC or impacts patients' satisfaction with their clinical encounter.

详细描述

We performed a prospective randomized block design pilot trail of usual contraceptive counseling versus usual counseling plus physician self-disclosure of personal intrauterine contraceptive use.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 44 Years(Adult)
性别
Female
接受健康志愿者
否

入选标准

  • •reproductive age
  • •currently sexually active
  • •scheduled for benign gynecology visit, annual exam, or family planning visit

排除标准

  • •seeking pregnancy within 1 year
  • •currently using IUC
  • •prior sterilization procedure
  • •currently pregnant

研究组 & 干预措施

Usual contraceptive counseling

Active Comparator

subjects received usual contraceptive counseling

干预措施: Usual contraceptive counseling (Behavioral)

Physician self-disclosure of IUC use

Experimental

subjects received usual contraceptive counseling plus intervention which was Physician self-disclosure of personal IUC use during the counseling

干预措施: Physician self-disclosure of personal IUC use (Behavioral)

结局指标

主要结局

Intrauterine contraceptive use

时间窗: immediately following clinical encounter and at 2 months

All subjects were surveyed to determine use of intrauterine contraceptive immediately after their clinical visit where contraceptive counseling was received and at 2 months after their clinical encounter to assess intrauterine contraceptive use.

次要结局

  • Satisfaction with clinical encounter(immediately following clinical encounter and at 2 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Mya Zapata

Clinical Lecturer

University of Michigan

研究点 (1)

Loading locations...

相似试验

进行中(未招募)
不适用
An extension study to enable patients to continue to receive Guanfacine Hydrochloride Extended Release tablets after completing either study SPD503-315 or SPD503-316.Attention Deficit/Hyperactivity Disorder (ADHD)MedDRA version: 17.1Level: LLTClassification code 10064104Term: ADHDSystem Organ Class: 100000004873
EUCTR2011-004668-31-PLShire Pharmaceutical Development Ltd249
进行中(未招募)
不适用
An extension study to enable patients to continue to receive Guanfacine Hydrochloride Extended Release tablets after completing either study SPD503-315 or SPD503-316.Attention Deficit/Hyperactivity Disorder (ADHD)MedDRA version: 14.0Level: LLTClassification code 10064104Term: ADHDSystem Organ Class: 10037175 - Psychiatric disorders
EUCTR2011-004668-31-SEShire Pharmaceutical Development Ltd249
进行中(未招募)
不适用
An extension study to enable patients to continue to receive Guanfacine Hydrocloride Extended Release tablets after completing either study SPD503-315 or SPD503-316.Attention Deficit/Hyperactivity Disorder (ADHD)MedDRA version: 14.1Level: LLTClassification code 10064104Term: ADHDSystem Organ Class: 10037175 - Psychiatric disorders
EUCTR2011-004668-31-NLShire Pharmaceutical Development Ltd249
已完成
3 期
A Phase 3, Open-label, Multicentre Study to Provide Access to Guanfacine Hydrochloride Extended Release for European Subjects with Attention-deficit/Hyperactivity Disorder (ADHD) who Participated in Study SPD503-315 or SPD503-316ADHD10009841Attention Deficit Hyperactivity Disorder
NL-OMON39256Shire21
进行中(未招募)
1 期
An extension study to enable patients to continue to receive Guanfacine Hydrocloride Extended Release tablets after completing either study SPD503-315 or SPD503-316.Attention Deficit/Hyperactivity Disorder (ADHD)MedDRA version: 17.1Level: LLTClassification code 10064104Term: ADHDSystem Organ Class: 100000004873
EUCTR2011-004668-31-BEShire Pharmaceutical Development Ltd249